First Tracks Biotherapeutics (NASDAQ:TRAX) — Market Cap & Net Worth
Market Cap & Net Worth: First Tracks Biotherapeutics (TRAX)
First Tracks Biotherapeutics (NASDAQ:TRAX) has a market capitalization of $1.14 Billion ($1.14 Billion) as of October 10, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8255 globally and #2395 in its home market, demonstrating a -9.68% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying First Tracks Biotherapeutics's stock price $32.01 by its total outstanding shares 35730843 (35.73 Million).
First Tracks Biotherapeutics Market Cap History: 2026 to 2026
First Tracks Biotherapeutics's market capitalization history from 2026 to 2026. Data shows growth from $1.14 Billion to $1.14 Billion (0.00% CAGR). Check TRAX live share price for real-time trading data and today's change.
First Tracks Biotherapeutics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how First Tracks Biotherapeutics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see TRAX cash generation efficiency for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TRAX by Market Capitalization
Companies near First Tracks Biotherapeutics in the global market cap rankings as of October 10, 2026. See First Tracks Biotherapeutics balance sheet quality to understand what proportion of total assets are financed by equity.
Key companies related to First Tracks Biotherapeutics by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $127.55 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $74.80 Billion USD.
- CSL Ltd (AU:CSL): Ranked #450 globally with a market cap of $62.29 Billion USD ( AU$88.04 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $127.55 Billion | $503.25 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $739.57 |
| #450 | CSL Ltd | AU:CSL | $62.29 Billion | AU$181.46 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $197.00 |
First Tracks Biotherapeutics Historical Marketcap From 2026 to 2026
Between 2026 and today, First Tracks Biotherapeutics's market cap moved from $1.14 Billion to $ 1.14 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.14 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 9th, 2026 the market cap of First Tracks Biotherapeutics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.14 Billion USD |
| MoneyControl | $1.14 Billion USD |
| MarketWatch | $1.14 Billion USD |
| marketcap.company | $1.14 Billion USD |
| Reuters | $1.14 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About First Tracks Biotherapeutics
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in bo… Read more